TABLE OF CONTENTS
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF EUROPE KNEE CARTILAGE REPAIR MARKET 22
1.4 CURRENCY AND PRICING 24
1.5 LIMITATIONS 24
1.6 MARKETS COVERED 25
2 EUROPE KNEE CARTILAGE REPAIR MARKET: SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 DBMR TRIPOD DATA VALIDATION MODEL 30
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.6 MULTIVARIATE MODELLING 34
2.7 TREATMENT SEGMENT LIFELINE CURVE 34
2.8 DBMR MARKET POSITION GRID 35
2.9 MARKET APPLICATION COVERAGE GRID 37
2.10 SECONDARY SOURCES 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 42
4.1 PESTEL ANALYSIS 43
4.2 PORTERS FIVE FORCES 44
5 EPIDERMIOLOGY 45
6 REIMBURSEMENT 46
6.1 OVERVIEW 46
7 EUROPE KNEE CARTILAGE REPAIR MARKET: REGULATIONS 48
8 MARKET OVERVIEW 50
8.1 DRIVERS 52
8.1.1 HIGH PREVALENCE OF KNEE DISORDERS 52
8.1.2 GROWING GERIATRIC POPULATION 53
8.1.3 GROWTH IN TECHNOLOGY DEVELOPMENT 53

8.2 RESTRAINTS 55
8.2.1 HIGH COST OF THE ORTHOPEDIC KNEE IMPLANTS AND SURGERIES 55
8.2.2 RISE IN CONCERN REGARDING METAL SENSITIVITY IN PATIENTS WITH KNEE IMPLANTS 55
8.3 OPPORTUNITIES 56
8.3.1 RISE IN AWARENESS OF KNEE TREATMENT IN EUROPE 56
8.3.2 RISE IN THE NUMBER OF KNEE SURGERIES 56
8.4 CHALLENGES 57
8.4.1 LACK OF SKILLED PROFESSIONALS 57
8.4.2 STRINGENT REGULATIONS 57
9 EUROPE KNEE CARTILAGE REPAIR MARKET, BY TREATMENT 59
9.1 OVERVIEW 60
9.2 CELL BASED 63
9.2.1 CHONDROCYTE TRANSPLANTATION 63
9.2.2 STEM CELL 63
9.2.3 GROWTH FACTORS 63
9.3 NON-CELL BASED 64
9.3.1 TISSUE SCAFFOLDS 64
9.3.2 CELL-FREE COMPOSITES 64
10 EUROPE KNEE CARTILAGE REPAIR MARKET, BY SURGERY 65
10.1 OVERVIEW 66
10.2 AUTOLOGOUS CHONDROCYTE IMPLANTATION 69
10.3 MICROFACTURE 69
10.4 DRILLING 70
10.5 ABRASION ARTHROPLASTY 70
10.6 OSTEOCHONDRAL ALLOGRAFT TRANSPLANTATION 71
10.7 OSTEOCHONDRAL AUTOGRAFT TRANSPLANTATION 71
10.8 OTHERS 71
11 EUROPE KNEE CARTILAGE REPAIR MARKET, BY DEVICES 72
11.1 OVERVIEW 73
11.2 IMPLANTS 76
11.2.1 BY FIXATION 77
11.2.1.1 CEMENTED 77
11.2.1.2 CEMENTLESS 77
11.2.1.3 HYBRID 77

11.2.2 BY MATERIAL 78
11.2.2.1 TITANIUM 78
11.2.2.2 POLYETHYLENE COBALT 78
11.2.2.3 COBALT-CHROMIUM BASED ALLOYS 78
11.2.2.4 CERAMICS 78
11.2.2.5 OTHERS 78
11.2.3 BY DESIGN 79
11.2.3.1 POSTERIOR-STABILIZED DESIGNS 79
11.2.3.2 CRUCIATE-RETAINING DESIGNS 79
11.2.3.3 BICRUCIATE-RETAINING DESIGNS 79
11.3 ARTHROSCOPY 79
11.3.1 TRIMMING OF DAMAGED ARTICULAR CARTILAGE 80
11.3.2 REMOVAL OR REPAIR OF A TORN MENISCUS 80
11.3.3 RECONSTRUCTION OF A TORN ANTERIOR CRUCIATE LIGAMENT 80
11.3.4 REMOVAL OF LOOSE FRAGMENTS OF BONE OR CARTILAGE 80
11.3.5 REMOVAL OF INFLAMED SYNOVIAL TISSUE 81
11.3.6 TREATMENT OF PATELLA (KNEECAP) PROBLEMS 81
11.3.7 TREATMENT OF KNEE SEPSIS (INFECTION) 81
11.4 BONE GRAFTS 81
11.4.1 ALLOGRAFT 81
11.4.2 SYNTHETIC 82
11.5 OSTEOTOMY 82
11.5.1 FEMUR 82
11.5.2 TIBIA 82
11.6 RESURFACING 83
11.7 ARTHRODESIS 83
11.8 OTHERS 83
12 EUROPE KNEE CARTILAGE REPAIR MARKET, BY APPLICATION 84
12.1 OVERVIEW 85
12.2 OSTEOARTHRITIS 88
12.3 RHEUMATOID ARTHRITIS 88
12.4 BONE TUMOR 89
12.5 FRACTURE 89
12.6 OSTEONECROSIS 90

13 EUROPE KNEE CARTILAGE REPAIR MARKET, BY END USER 91
13.1 OVERVIEW 92
13.2 HOSPITALS 95
13.2.1 BY TYPE 95
13.2.1.1 PUBLIC 95
13.2.1.2 PRIVATE 96
13.2.2 BY SIZE 96
13.2.2.1 LARGE 96
13.2.2.2 MEDIUM 96
13.2.2.3 SMALL 96
13.3 AMBULATORY SURGICAL CENTERS 96
13.4 INDEPENDENT CENTERS 97
14 EUROPE KNEE CARTILAGE REPAIR MARKET, BY DISTRIBUTION CHANNEL 98
14.1 OVERVIEW 99
14.2 DIRECT SALES 102
14.3 THIRD PARTY DISTRIBUTORS 102
14.4 ONLINE SALES 102
14.5 OTHERS 103
15 EUROPE KNEE CARTILAGE REPAIR MARKET BY COUNTRY 104
15.1 EUROPE 104
15.1.1 GERMANY 109
15.1.2 SWITZERLAND 116
15.1.3 BELGIUM 122
15.1.4 U.K. 128
15.1.5 NETHERLANDS 134
15.1.6 FRANCE 140
15.1.7 SPAIN 146
15.1.8 ITALY 152
15.1.9 SWEDEN 158
15.1.10 TURKEY 164
15.1.11 RUSSIA 170
15.1.12 REST OF EUROPE 176
16 EUROPE KNEE CARTILAGE REPAIR MARKET: COMPANY LANDSCAPE 177
16.1 COMPANY SHARE ANALYSIS: EUROPE 177
17 SWOT ANALYSIS 178

18 COMPANY PROFILE 179
18.1 ZIMMER BIOMET 179
18.1.1 COMPANY SNAPSHOT 179
18.1.2 REVENUE ANALYSIS 179
18.1.3 PRODUCT PORTFOLIO 180
18.1.4 RECENT DEVELOPMENTS 181
18.2 JOHNSON & JOHNSON SERVICES, INC. 182
18.2.1 COMPANY SNAPSHOT 182
18.2.2 REVENUE ANALYSIS 182
18.2.3 PRODUCT PORTFOLIO 183
18.2.4 RECENT DEVELOPMENT 183
18.3 CONMED 184
18.3.1 COMPANY SNAPSHOT 184
18.3.2 REVENUE ANALYSIS 184
18.3.3 PRODUCT PORTFOLIO 185
18.3.4 RECENT DEVELOPMENTS 185
18.4 SMITH & NEPHEW 186
18.4.1 COMPANY SNAPSHOT 186
18.4.2 REVENUE ANALYSIS 186
18.4.3 PRODUCT PORTFOLIO 187
18.4.4 RECENT DEVELOPMENTS 187
18.5 STRYKER 189
18.5.1 COMPANY SNAPSHOT 189
18.5.2 REVENUE ANALYSIS 189
18.5.3 PRODUCT PORTFOLIO 190
18.5.4 RECENT DEVELOPMENTS 190
18.6 ARTHREX, INC. 191
18.6.1 COMPANY SNAPSHOT 191
18.6.2 PRODUCT PORTFOLIO 191
18.6.3 RECENT DEVELOPMENTS 191
18.7 B. BRAUN MELSUNGEN AG 192
18.7.1 COMPANY SNAPSHOT 192
18.7.2 PRODUCT PORTFOLIO 192
18.7.3 RECENT DEVELOPMENTS 192
18.8 BIOTISSUE 193
18.8.1 COMPANY SNAPSHOT 193
18.8.2 PRODUCT PORTFOLIO 193
18.8.3 RECENT DEVELOPMENTS 193

18.9 HY2CARE 194
18.9.1 COMPANY SNAPSHOT 194
18.9.2 PRODUCT PORTFOLIO 194
18.9.3 RECENT DEVELOPMENTS 194
18.10 JRI ORTHOPAEDICS 195
18.10.1 COMPANY SNAPSHOT 195
18.10.2 PRODUCT PORTFOLIO 195
18.10.3 RECENT DEVELOPMENTS 195
18.11 MATHYS LTD BETTLACH 196
18.11.1 COMPANY SNAPSHOT 196
18.11.2 PRODUCT PORTFOLIO 196
18.11.3 RECENT DEVELOPMENTS 196
18.12 MEDACTA INTERNATIONAL 197
18.12.1 COMPANY SNAPSHOT 197
18.12.2 PRODUCT PORTFOLIO 197
18.12.3 RECENT DEVELOPMENTS 197
18.13 MERIL LIFE SCIENCES PVT LTD. 199
18.13.1 COMPANY SNAPSHOT 199
18.13.2 PRODUCT PORTFOLIO 199
18.13.3 RECENT DEVELOPMENTS 199
18.14 REGENTIS BIOMATERIALS LTD. 200
18.14.1 COMPANY SNAPSHOT 200
18.14.2 PRODUCT PORTFOLIO 200
18.14.3 RECENT DEVELOPMENTS 200
18.15 WALDEMAR LINK GMBH & CO. KG 201
18.15.1 COMPANY SNAPSHOT 201
18.15.2 PRODUCT PORTFOLIO 201
18.15.3 RECENT DEVELOPMENTS 201
19 QUESTIONNAIRE 202
20 RELATED REPORTS 206

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.